N,N-Diethyl-N-Methyl-2-((4-(2-(Octyloxy)Benzamido)Benzoyl)Oxy)Ethanaminium Bromide N,N-二乙基-N-甲基-2-((4((2-(辛氧基)苯甲酰氨基)苯甲酰)氧基)乙铵溴化物
CAS 26095-59-0 MFCD00211142
化学结构图
SMILES: [Br-].CCCCCCCCOC1=CC=CC=C1C(=O)NC1C=CC(=CC=1)C(=O)OCC[N+](C)(CC)CC
化学属性
| Mol. Formula | C29H43N2O4.Br |
|---|---|
| Mol. Weight | 563.65 |
别名和识别编码
| Chemical Name | N,N-Diethyl-N-Methyl-2-((4-(2-(Octyloxy)Benzamido)Benzoyl)Oxy)Ethanaminium Bromide |
|---|---|
| CAS Number | 26095-59-0 |
| Synonym | Doralin Spasen N,N-Diethyl-N-methy-2-[[4-[[2-(octyloxy)benzoyl]amino]benzoyl]oxy]ethanaminium Bromide SP-63 Otilonium Bromide Spasmoctyl Pasminox Diethyl(2-hydroxyethyl)methylammonium bromide Spasmomen Menoctyl |
| Chemical Name Translation | N,N-二乙基-N-甲基-2-((4((2-(辛氧基)苯甲酰氨基)苯甲酰)氧基)乙铵溴化物 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- Amines
- Inhibitors
- Pharmaceuticals
- Intermediates & Fine Chemicals,
产品应用
- Octylonium bromide is an antimuscarinic. Octylonium bromide is a platelet-activating factor antagonist as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agent.
相关文献及参考
- [2]. Clave, P., et al., Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther, 2011. 34(4): p. 432-42.
- [3]. Lindqvist, S., et al., The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol, 2002. 137(7): p. 1134-42.
- [4]. Gandia, L., et al., Otilonium: a potent blocker of neuronal nicotinic ACh receptors in bovine chromaffin cells. Br J Pharmacol, 1996. 117(3): p. 463-470.
- Manzini, S., et al.: Drugs Exp. Clin. Res., 14, 265 (1988),
- [1]. Battaglia, G., et al., Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-co
- [1]. Battaglia, G., et al., Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther, 1998. 12(10): p. 1003-10.
安全信息
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intravenous SPECIES OBSERVED
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : >1500 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/page/year: 15,417,1979
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Mammal - species unspecified DOSE/DURATION : 650 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : FRPSAX Farmaco, Edizione Scientifica. (Casella Postale 227, 27100 Pavia, Italy) V.8-43 1953-88 For publisher information, see FRMCE8 Volume(issue)/page/year: 39,3,1984
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Mammal - species unspecified DOSE/DURATION : 85 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : FRPSAX Farmaco, Edizione Scientifica. (Casella Postale 227, 27100 Pavia, Italy) V.8-43 1953-88 For publisher information, see FRMCE8 Volume(issue)/page/year: 39,3,1984
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - rat DOSE/DURATION : >1650 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : MDACAP Medicamentos de Actualidad. (J.R. Prous, S.A., Apartado de Correos 540, 08080 Barcelona, Spain) V.1- 1965- Volume(issue)/pag
京ICP备2020036287号